Drug Profile
Research programme: MM 302 companion diagnostics - Merrimack Pharmaceuticals
Alternative Names: 64Cu-Liposomal PET Agent - Merrimack Pharmaceuticals; DX-929; MM-DX-929Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merrimack Pharmaceuticals
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Image enhancers; Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HER2 positive breast cancer; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Her2-positive-breast-cancer (Diagnosis) in USA (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in USA (IV)
- 11 Dec 2012 Pharmacodynamics/pharmacokinetics data from a preclinical study in Breast cancer (Diagnosis) released by Merrimack Pharmaceuticals